Abiraterone acetate is a potent oral CYP17 inhibitor that is metabolized into abiraterone in vivo and has 10-30 times more inhibitory activity against 17α-hydroxylase /C17, 20-lyase (CYP17) than ketoconazole. Clinical studies have shown that abiraterone acetate can significantly reduce prostate-specific antigen (PSA) levels in prostate cancer patients and help shrink tumors, extending the life of patients with advanced prostate cancer by several years. Abiraterone acetate is the precursor drug of abiraterone, which targets the androgen-receptor signaling pathway. Abiraterone is a highly selective and potent inhibitor of cytochrome oxidase CYP17, and its inhibition effect is irreversible, which is 10 to 30 times stronger than the non-selective inhibitor ketoconazole.

Abiraterone acetate is a CYP17 inhibitor that, in combination with prednisone, can be used to treat prostate cancer in patients who have previously received docetaxel chemotherapy to metastasize. Abiraterone acetate is a precursor drug that can be converted into abiraterone after entering the body, which is an androgen biosynthesis inhibitor by inhibiting the activity of CYP17 enzyme, and thus inhibiting androgen biosynthesis.